🟣Introduction to anemia 🟣Iron deficiency anemia 🟣Megaloblastic anemia 🟣Introduction and classification of Hemolytic anemias 🟣Hemolytic anemias due to the red cell membrane disorders 🟣Thalassemia syndrome 🟣Sickle cell disease 🟣Hemolytic anemia due to red cell enzyme deficiencies 🟣Immunohemolytic anemia 🟣Fragmentation syndrome 🟣Parxoysmal nocturnal hemoglobinuria 🟣Aplastic anemia 🟣Pure red cell aplasia 🟣Sideroblastic anemia 🟣Anemia of chronic disease 🟣Polycythemia
🟣Introduction to anemia 🟣Iron deficiency anemia 🟣Megaloblastic anemia 🟣Introduction and classification of Hemolytic anemias 🟣Hemolytic anemias due to the red cell membrane disorders 🟣Thalassemia syndrome 🟣Sickle cell disease 🟣Hemolytic anemia due to red cell enzyme deficiencies 🟣Immunohemolytic anemia 🟣Fragmentation syndrome 🟣Parxoysmal nocturnal hemoglobinuria 🟣Aplastic anemia 🟣Pure red cell aplasia 🟣Sideroblastic anemia 🟣Anemia of chronic disease 🟣Polycythemia
BY HEMATOLOGY WORLD🔬
Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283
China’s stock markets are some of the largest in the world, with total market capitalization reaching RMB 79 trillion (US$12.2 trillion) in 2020. China’s stock markets are seen as a crucial tool for driving economic growth, in particular for financing the country’s rapidly growing high-tech sectors.Although traditionally closed off to overseas investors, China’s financial markets have gradually been loosening restrictions over the past couple of decades. At the same time, reforms have sought to make it easier for Chinese companies to list on onshore stock exchanges, and new programs have been launched in attempts to lure some of China’s most coveted overseas-listed companies back to the country.
Spiking bond yields driving sharp losses in tech stocks
A spike in interest rates since the start of the year has accelerated a rotation out of high-growth technology stocks and into value stocks poised to benefit from a reopening of the economy. The Nasdaq has fallen more than 10% over the past month as the Dow has soared to record highs, with a spike in the 10-year US Treasury yield acting as the main catalyst. It recently surged to a cycle high of more than 1.60% after starting the year below 1%. But according to Jim Paulsen, the Leuthold Group's chief investment strategist, rising interest rates do not represent a long-term threat to the stock market. Paulsen expects the 10-year yield to cross 2% by the end of the year.
A spike in interest rates and its impact on the stock market depends on the economic backdrop, according to Paulsen. Rising interest rates amid a strengthening economy "may prove no challenge at all for stocks," Paulsen said.
